Company / Interest Expense
Corbus Pharmaceuticals Holdings, Inc. Interest Expense History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$2.7M
FY2022
5-year range
$0 / $2.7M
FY2018-FY2022
Trend
+140.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $0 to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2022 with a 5-year CAGR of +306.5%.
Increased from $0 to $3M over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +306.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +306.5%, indicating consistent growth.
- In FY2022, interest expense increased 140.5% year-over-year.
- Lowest interest expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $2.7M | +140.5% |
| FY2021 | $1.1M | - |
| FY2020 | $0 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $2.4K | +0.0% |
| FY2016 | $2.4K | -89.8% |
| FY2015 | $24.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026